• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Roy S. Herbst, John V. Heymach, Scott Michael Lippman
  • Medicine
  • The New England journal of medicine
  • 2008 (First Publication: 25 September 2008)
  • From the Departments of Thoracic/Head and Neck Medical Oncology (R.S.H., J.V.H., S.M.L.), Cancer Biology (R.S.H., J.V.H.), and Clinical Cancer Prevention (S.M.L.), University of Texas M.D. AndersonExpand
  • Lauren Averett Byers, Lixia Diao, +31 authors John V. Heymach
  • Medicine, Biology
  • Clinical Cancer Research
  • 2012 (First Publication: 22 October 2012)
  • Purpose: Epithelial–mesenchymal transition (EMT) has been associated with metastatic spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a robust 76-gene EMT signatureExpand
  • Jeffrey A. Engelman, Kreshnik Zejnullahu, +15 authors Pasi A. Jänne
  • Medicine
  • Cancer research
  • 2007 (First Publication: 15 December 2007)
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers. In particular, cancers with specificExpand
  • James Welsh, Ritsuko R Komaki, +15 authors Baldassarre Stea
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2013 (First Publication: 1 March 2013)
  • PURPOSE Brain metastasis (BM) is a leading cause of death from non-small-cell lung cancer (NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) contributes to radiationExpand
  • Jeffrey A. Engelman, Toru Mukohara, +13 authors Pasi A. Jänne
  • Biology, Medicine
  • The Journal of clinical investigation
  • 2006 (First Publication: 2 October 2006)
  • EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to EGFR inhibitors gefitinib and erlotinib. A secondary mutation, T790M, has been associated with acquired resistance butExpand
  • Roy S. Herbst, Yan Sun, +15 authors Bruce E. Johnson
  • Medicine
  • The Lancet. Oncology
  • 2010 (First Publication: 1 July 2010)
  • BACKGROUND Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosineExpand
  • Ferdinandos Skoulidis, Lauren Averett Byers, +34 authors John V. Heymach
  • Biology, Medicine
  • Cancer discovery
  • 2015 (First Publication: 11 June 2015)
  • UNLABELLED The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung adenocarcinoma are poorly characterized. We performed an integrative analysis of genomic, transcriptomic, andExpand